Evidence map›Paper›PMID 38129082›Full record

ArticleBMJ case reports2023

Felbamate urolithiasis.

Ilana Bergelson, Chance Walker, Elizabeth L Frank, Ryan Steinberg

Open access · greenAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Ilana BergelsonDepartment of Urology, The University of Iowa Hospitals and Clinics, Iowa City, lowa, USA ilana-bergelson@uiowa.edu.
Chance WalkerDepartment of Pathology, University of Utah Health, Salt Lake City, Utah, USA.
Elizabeth L FrankARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA.
Ryan SteinbergDepartment of Urology, The University of Iowa Hospitals and Clinics, Iowa City, lowa, USA.
University of Iowa Hospitals and Clinics · USARUP Institute for Clinical and Experimental PathologyARUP Laboratories (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced nephrolithiasis is an important consideration in recurrent stone formers with polypharmacy. While felbamate nephrolithiasis has previously been published in the paediatric population, we present the oldest published case of a felbamate stone in an adult, a man in his 30s with Lennox-Gastaut syndrome. Even with moderate dosing, high drug serum levels can occur. Performing at least one stone analysis remains a critical component to care in these patients. Urologists should have a high index of suspicion for drug stone when stone analysis returns indeterminate characterisation in the absence of infection. Close communication with neurology is key to preventing recurrent stone disease.

Indexed as

EpilepsyFelbamateNephrolithiasisUrolithiasisAdultAnticonvulsantsHumansMalePhenylcarbamatesPropylene GlycolsAnticonvulsantsFelbamatePhenylcarbamatesPropylene GlycolsEpilepsy and seizuresUrological surgery

Identifiers

PMID38129082
OpenAlexW4390064373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.